SAILIFE

Sai Life Science Share Price

 

 

Invest in Sai Life Science with 3.12X leverage

Invest with MTF
Sai Life Science live price: ₹959.95. It opened at ₹976 vs previous close ₹977; intraday high/low: ₹976/₹944. The 50 & 200 DMA stand at ₹955.32/₹873.65.

Sai Life Science Performance

  • Today's Low
  • ₹944
  • Today's High
  • ₹976
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹1,084
  • Open Price₹976
  • Previous Close₹977
  • Volume635,904
  • 50 DMA₹955.32
  • 100 DMA₹924.14
  • 200 DMA₹873.65

Investment Returns

  • Over 1 Month -3.84%
  • Over 3 Month + 6.63%
  • Over 6 Month + 8.21%
  • Over 1 Year + 26.85%

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61.1
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 20,330
  • P/B Ratio
  • 8.6
  • Average True Range
  • 38.68
  • EPS
  • 16.01
  • Dividend Yield
  • 0
  • MACD Signal
  • 15.62
  • RSI
  • 46.25
  • MFI
  • 52.94

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹959.95
-16.9 (-1.73%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹983.11
  • 50 Day
  • ₹955.32
  • 100 Day
  • ₹924.14
  • 200 Day
  • ₹873.65

Resistance and Support

959.97 Pivot Speed
  • R3 1,007.73
  • R2 991.82
  • R1 975.88
  • S1 944.03
  • S2 928.12
  • S3 912.18

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 2,169.86 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 11% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-06 Quarterly Results
2025-08-07 Quarterly Results
2025-05-13 Audited Results
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

34.7%
27.57%
3.24%
21.41%
5.94%
7.14%

Sai Life Science FAQs

Sai Life Science share price is ₹959 As on 03 April, 2026 | 04:17

The Market Cap of Sai Life Science is ₹20329.7 Cr As on 03 April, 2026 | 04:17

The P/E ratio of Sai Life Science is 61.1 As on 03 April, 2026 | 04:17

The PB ratio of Sai Life Science is 8.6 As on 03 April, 2026 | 04:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23